Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 213

Sort by

Sort Order Select

Journal Articles

PIKfyve inhibition in myeloma disrupts autophagy and the lysosome, increasing MHC expression and cholesterol metabolism

Cecilia Bonolo De Campos, Ruijuan He, Tessa Josephine Pelino, Dor David Abelman, Zhihua Li, Daniel K C Lee, Ding Yan Wang, Michael St. Paul, Jeffrey Bruce, Craig D Simpson, Leanne Wybenga-Groot, Michael F. Moran, Rodger E Tiedemann, Trevor Pugh, Tak W. Mak, Olga Issakova, Nikolai Sepetov, Suzanne Trudel, A Keith Stewart

Blood blood.2025030061.

https://doi.org/10.1182/blood.2025030061

Published: 2025

Includes: Supplemental data

Journal Articles

Safety and efficacy of elranatamab + nirogacestat in patients with relapsed or refractory multiple myeloma: Results from the Phase 1b MagnetisMM-4 study

Ola Landgren, Suzanne Trudel, Jacalyn Rosenblatt, Arleigh McCurdy, Sumit Madan, Syed Abbas Ali, Nizar Bahlis, Eli Gabayan, Robert Vescio, Melissa O'Gorman, Shinta Cheng, Sibo Jiang, Margaret Hoyle, Jay Cheng, Erik Vandendries, Noopur Raje

Blood (2025) 146 (Supplement 1): 4058.

https://doi.org/10.1182/blood-2025-4058

Published: 2025

Journal Articles

Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up

Blood (2025) 146 (Supplement 1): 698.

https://doi.org/10.1182/blood-2025-698

Published: 2025

Journal Articles

Autophagy/lysosome disruption via pikfyve inhibition in multiple myeloma

Cecilia Bonolo De Campos, Kuo Chien Daniel Lee, Ruijuan He, Tessa Pelino, Dor Abelman, Zhihua Li, Ding Wang, Michael St. Paul, Jeffrey Bruce, Craig Simpson, Leanne Wybeng-Groot, Michael Moran, Trevor Pugh, Tak Mak, Olga Issakova, Nikolai Sepetov, Suzanne Trudel, Keith Stewart

Blood (2025) 146 (Supplement 1): 3316.

https://doi.org/10.1182/blood-2025-3316

Published: 2025

Journal Articles

Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma

Blood (2025) 146 (Supplement 1): 2178.

https://doi.org/10.1182/blood-2025-2178

Published: 2025

Journal Articles

Do chip mutations predict frailty and toxicity in transplant-eligible patients with multiple myeloma?

Steven Chun-Min Shih, Harjot Singh Vohra, Sahar Khan, Salman Basrai, Esther Masih-Khan, Anup Devasia, Donna Reece, Suzanne Trudel, Keith Stewart, Sita Bhella, Vishal Kukreti, Chloe Yang, Guido Lancman, Rodger Tiedemann, Anca Prica, Eugene Leung, Aaron Schimmer, Sagi Abelson, Christine Chen

Blood (2025) 146 (Supplement 1): 5773.

https://doi.org/10.1182/blood-2025-5773

Published: 2025

Journal Articles

Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial

Cyrille Touzeau, Hanlon Sia, Sebastian Grosicki, Paz Ribas, Carmine Liberatore, Paula Rodriguez-Otero, Suzanne Trudel, Takashi Ikeda, Antonio Lazzaro, Karen Gogat-Marchant, Sharon T. Sullivan, Domenico Cieri, Eric Leip, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 2283.

https://doi.org/10.1182/blood-2025-2283

Published: 2025

Journal Articles

Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study

Blood (2025) 146 (Supplement 1): 2264.

https://doi.org/10.1182/blood-2025-2264

Published: 2025

Journal Articles

Ultra-deep whole-genome sequencing of cell-free DNA recovers most bone marrow-derived mutations in newly diagnosed multiple myeloma

Dor Abelman, David Scott, Jenna Eagles, Stephanie Pedersen, Aimée Wong, Saumil Shah, Cecilia Bonolo De Campos, Darrel White, Irwindeep Sandhu, Kevin Song, Alli Murugesan, Anthony Reiman, Suzanne Trudel, Trevor Pugh

Blood (2025) 146 (Supplement 1): 495.

https://doi.org/10.1182/blood-2025-495

Published: 2025

Journal Articles

Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change

Suzanne Trudel, Vania Hungria, María-Victoria Mateos, Chee Paul Lin, Julie Byrne, James Parker, Molly Purser, Sandhya Sapra, Farrah Pompilus, Sumita Roy-Ghanta, Giulia Fulci, Joanna Opalinska, Neal Sule, Brandon Kremer, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 5823.

https://doi.org/10.1182/blood-2025-5823

Published: 2025

Journal Articles

Sensitive peripheral residual disease (PRD) detection using clonotypic mass spectrometry (EasyM) in patients with newly diagnosed multiple myeloma (NDMM)

Rintu Sharma, Esther Masih-Khan, Harjot Singh Vohra, Sita Bhella, Christine Chen, Chloe Yang, Guido Lancman, Keith Stewart, Vishal Kukreti, Vathany Kulasingam, Abir Khaled, Zac McDonald, Liqiang Yang, Arleigh McCurdy, Suzanne Trudel

Blood (2025) 146 (Supplement 1): 2250.

https://doi.org/10.1182/blood-2025-2250

Published: 2025

Journal Articles

Tumor clearance, T-cell fitness, and minimal residual disease (MRD) outcomes in patients with relapsed/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: Biomarker analyses from CAMMA 1 Arm B

Simon Harrison, Caroline Hasselbalch Riley, Hira Mian, Andrew Spencer, Noa Lavi, Laura Paris, Jana Mihalyova, Rakesh Popat, Monika Szarejko, Sebastian Grosicki, Kihyun Kim, Irwindeep Sandhu, Sammy Chebon, Tulika Tyagi, Paresh Sewpaul, Leanne Richardson, Kerstin Trunzer, Ameet Mishra, Suzanne Trudel

Blood (2025) 146 (Supplement 1): 252.

https://doi.org/10.1182/blood-2025-252

Published: 2025

Journal Articles

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 250.

https://doi.org/10.1182/blood-2025-250

Published: 2025

Journal Articles

Pharmacodynamic activity and clinical benefits of mezigdomide in high-risk biomarker subgroups from the CC-92480-MM-001 study

Tracy Chow, Nicholas Stong, Keyur Desai, Saleh Tamim, Chad Bjorklund, Joseph Hadala, Cynthia Donahue, Phillip Koo, Erica Petrlik, Jessica Katz, Anita Gandhi, Suzanne Trudel, Nizar Bahlis, Paul Richardson, Michael Amatangelo

Blood (2025) 146 (Supplement 1): 5697.

https://doi.org/10.1182/blood-2025-5697

Published: 2025

Journal Articles

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide

Blood (2024) 144 (Supplement 1): 4731.

https://doi.org/10.1182/blood-2024-199282

Published: 2024

Journal Articles

Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin

Anup Joseph Devasia, Olsen Chan, Harjot Vohra, Esther Masih-Khan, Chloe Yang, Sita Bhella, Rodger E Tiedemann, Vishal Kukreti, Christine I Chen, Keith Stewart, Donna Reece, Suzanne Trudel, Guido Lancman

Blood (2024) 144 (Supplement 1): 3787.

https://doi.org/10.1182/blood-2024-209131

Published: 2024

Journal Articles

Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)

Donna E Reece, Giovanni Piza Rodriguez, Mariela A Pantoja, Eshetu G Atenafu, Darrell White, Irwindeep Sandhu, Julie Stakiw, Michael Sebag, Terrance Comeau, Kevin Song, Jean Roy, Martha L Louzada, Arleigh McCurdy, Vishal Kukreti, Suzanne Trudel, Anca Prica, Rodger E Tiedemann, Christine I Chen

Blood (2024) 144 (Supplement 1): 3376.

https://doi.org/10.1182/blood-2024-206247

Published: 2024

Journal Articles

Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma

Dor D. Abelman, Jenna Eagles, Aimee Wong, Saumil Shah, Stephanie Pedersen, Sarah Bridges, Cecilia Bonolo De Campos, Darrell White, Irwindeep Sandhu, Kevin Song, Zac McDonald, Abir Khaled, Liqiang Yang, Alli Murugesan, Anthony Reiman, Suzanne Trudel, Trevor J. Pugh

Blood (2024) 144 (Supplement 1): 3338.

https://doi.org/10.1182/blood-2024-208740

Published: 2024

Journal Articles

Handgrip Strength - Finetuning an Objective Measure of Frailty in Transplant-Eligible Patients with Multiple Myeloma

Steven Shih, Harjot Vohra, Anup Joseph Devasia, Sahar Khan, Eshetu Atenafu, Donna Reece, Suzanne Trudel, A. Keith Stewart, Sita D. Bhella, Vishal Kukreti, Chloe Yang, Rodger E. Tiedemann, Anca Prica, Eugene Leung, Christine I Chen

Blood (2024) 144 (Supplement 1): 4690.

https://doi.org/10.1182/blood-2024-198797

Published: 2024

Journal Articles

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

Blood (2024) 144 (Supplement 1): 1021.

https://doi.org/10.1182/blood-2024-199542

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

PIKfyve inhibition in myeloma disrupts autophagy and the lysosome, increasing MHC expression and cholesterol metabolism

Safety and efficacy of elranatamab + nirogacestat in patients with relapsed or refractory multiple myeloma: Results from the Phase 1b MagnetisMM-4 study

Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up

Autophagy/lysosome disruption via pikfyve inhibition in multiple myeloma

Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma

Do chip mutations predict frailty and toxicity in transplant-eligible patients with multiple myeloma?

Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial

Deep responses and durable outcomes in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the Phase 3 dreamm-8 study

Ultra-deep whole-genome sequencing of cell-free DNA recovers most bone marrow-derived mutations in newly diagnosed multiple myeloma

Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change

Sensitive peripheral residual disease (PRD) detection using clonotypic mass spectrometry (EasyM) in patients with newly diagnosed multiple myeloma (NDMM)

Tumor clearance, T-cell fitness, and minimal residual disease (MRD) outcomes in patients with relapsed/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: Biomarker analyses from CAMMA 1 Arm B

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma

Pharmacodynamic activity and clinical benefits of mezigdomide in high-risk biomarker subgroups from the CC-92480-MM-001 study

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide

Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin

Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)

Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma

Handgrip Strength - Finetuning an Objective Measure of Frailty in Transplant-Eligible Patients with Multiple Myeloma

Cevostamab in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study Demonstrate Clinically Meaningful Activity and Manageable Safety and Inform the Doses and Regimen for Combination Studies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only